Infant Bacterial Therapeutics ABIFTBF 29 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates IFTBF with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, Infant Bacterial Therapeutics AB ranks worse than 105932.1% on this metric.
Infant Bacterial Therapeutics AB (OTCPK:IFTBF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Infant Bacterial Therapeutics AB EBITDA Margin % Related Terms
Infant Bacterial Therapeutics AB EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infant Bacterial Therapeutics AB EBITDA Margin % Chart
IFTBF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Infant Bacterial Therapeutics AB EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Infant Bacterial Therapeutics AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Infant Bacterial Therapeutics AB (IFTBF) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Infant Bacterial Therapeutics AB and its competitors. According to the industry distribution chart, Infant Bacterial Therapeutics AB ranks #999999 out of 944 companies in the Biotechnology industry.
Is Infant Bacterial Therapeutics AB's EBITDA Margin % too high?
Infant Bacterial Therapeutics AB's current EBITDA Margin % is 0.00%. Based on the distribution chart, Infant Bacterial Therapeutics AB ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Infant Bacterial Therapeutics AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Infant Bacterial Therapeutics AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Infant Bacterial Therapeutics AB ranks #999999 out of 944 companies for EBITDA Margin %. This places Infant Bacterial Therapeutics AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Infant Bacterial Therapeutics AB and its competitors. Infant Bacterial Therapeutics AB's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infant Bacterial Therapeutics AB stock overvalued right now?
Infant Bacterial Therapeutics AB (IFTBF) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Infant Bacterial Therapeutics AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Infant Bacterial Therapeutics AB (IFTBF), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Infant Bacterial Therapeutics AB Business Description
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance, Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118, and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
29GF Score
Get the complete analysis for IFTBF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IFTBF has been successfully added to your 
